These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26909596)

  • 1. Drug resistance in cancer: molecular evolution and compensatory proliferation.
    Friedman R
    Oncotarget; 2016 Mar; 7(11):11746-55. PubMed ID: 26909596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of acquired resistance to anti-cancer therapy.
    Foo J; Michor F
    J Theor Biol; 2014 Aug; 355():10-20. PubMed ID: 24681298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing mutational and adaptive landscapes and the genesis of cancer.
    Liggett LA; DeGregori J
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.
    Venkatesan S; Swanton C; Taylor BS; Costello JF
    Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28289245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.
    Aktipis CA; Kwan VS; Johnson KA; Neuberg SL; Maley CC
    PLoS One; 2011; 6(11):e26100. PubMed ID: 22125594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.
    Foo J; Michor F
    PLoS Comput Biol; 2009 Nov; 5(11):e1000557. PubMed ID: 19893626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype- or Phenotype-Targeting Anticancer Therapies? Lessons from Tumor Evolutionary Biology.
    Escargueil AE; Prado S; Dezaire A; Clairambault J; Larsen AK; Soares DG
    Curr Pharm Des; 2016; 22(44):6625-6644. PubMed ID: 27587198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
    Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
    Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
    Berns K; Bernards R
    Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint.
    Rueff J; Rodrigues AS
    Methods Mol Biol; 2016; 1395():1-18. PubMed ID: 26910065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of cancer evolution for drug development.
    Turajlic S; Swanton C
    Nat Rev Drug Discov; 2017 Jul; 16(7):441-442. PubMed ID: 28450743
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution.
    Huang S
    Prog Biophys Mol Biol; 2012 Sep; 110(1):69-86. PubMed ID: 22579660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies for targeting drug combinations to overcome mutation-driven drug resistance.
    Wang L; Wang H; Song D; Xu M; Liebmen M
    Semin Cancer Biol; 2017 Feb; 42():44-51. PubMed ID: 27840276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.
    Ramos P; Bentires-Alj M
    Oncogene; 2015 Jul; 34(28):3617-26. PubMed ID: 25263438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis and therapy.
    Schmitt CA; Lowe SW
    J Pathol; 1999 Jan; 187(1):127-37. PubMed ID: 10341713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of targeted cancer therapy.
    Bozic I; Allen B; Nowak MA
    Trends Mol Med; 2012 Jun; 18(6):311-6. PubMed ID: 22595628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.
    Chisholm RH; Lorenzi T; Clairambault J
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2627-45. PubMed ID: 27339473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
    Bagrodia S; Smeal T; Abraham RT
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.